View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Accenture Plc: 1 director

A director at Accenture Plc sold 6,057 shares at 241.225USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Nicolas David ... (+2)
  • Nicolas David
  • Nicolas Thorez

ODDO : Shift to more favourable cycle to ease AI pressure on sector va...

While we do not deny the uncertainties and risks associated with artificial intelligence (pricing pressures, organisational change, etc.), we remain constructive on this issue, given the significant volume opportunities in prospect for the sector with the integration of agentic AI. Moreover, improving growth momentum in 2026 should reduce pressure on sector valuations (discount >30% vs Stoxx 600 vs a premium of 10% four years ago). On this basis, we have upgraded Bechtle (Outperform vs Neutral),...

Nicolas David ... (+2)
  • Nicolas David
  • Nicolas Thorez

ODDO : L’entrée dans un cycle plus favorable devrait réduire la pressi...

Sans nier les incertitudes et risques liés à l’IA (pressions tarifaires, changements organisationnels, etc.), nous restons constructifs sur cette thématique tant les opportunités de volumes autour de l’intégration de l’IA agentique sont importantes pour le secteur. D’autant plus que l’amélioration de la dynamique de croissance en 2026 devrait permettre de réduire la pression sur les valorisations du secteur (décote >30% vs Stoxx 600 contre une prime de 10% il y a 4 ans). Dans ce contexte, nous r...

 PRESS RELEASE

Da Vinci 5 Cleared for Cardiac Procedures

Da Vinci 5 Cleared for Cardiac Procedures FDA 510(k) clearance expands da Vinci 5 indications to include certain cardiac procedures SUNNYVALE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci 5 system for certain cardiac procedures, including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization.         Cardiovascular disease remains the l...

 PRESS RELEASE

20 Million Patients Benefit from da Vinci Surgery Globally

20 Million Patients Benefit from da Vinci Surgery Globally Achievement reflects the dedication of surgeons and care teams worldwide to improving patient outcomes through use of Intuitive’s minimally invasive technologies SUNNYVALE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that more than 20 million patients worldwide have been operated on by surgeons using da Vinci surgical systems. The milestone was reached as of the end of 2025, with more than 3.1 mil...

 PRESS RELEASE

Intuitive Announces Fourth Quarter Earnings

Intuitive Announces Fourth Quarter Earnings SUNNYVALE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2025. Q4 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%.The Company placed 532 da Vinci surgical systems, compared with...

Accenture plc - November 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

 PRESS RELEASE

Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Resu...

Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Financial and Operational Highlights Fourth quarter 2025 worldwide procedures (da Vinci and Ion combined) grew approximately 18...

Ghada Ben Sedrine ... (+2)
  • Ghada Ben Sedrine
  • Nicolas David
Ghada Ben Sedrine ... (+2)
  • Ghada Ben Sedrine
  • Nicolas David
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch